Revive Therapeutics Updates Its Psilocybin Pharmaceutical Programs
Revive Therapeutics, a publicly owned company that trades under the symbol of RVVTF, is focused on developing alternative therapeutics for specific medical needs along with rare disorders. The company recently provided an update pertaining to its psilocybin pharmaceutical development programs. Here’s a quick look at why the Revive’s update is important for psychedelics investors.
Details Of The Update
Revive’s public relations team issued a statement indicating the company is working hard to develop its psilocybin product pipeline with the hope of helping patients overcome mental illness, neurological disorders and substance abuse. The company is now working toward starting its initial clinical study to evaluate the use of psilocybin for treating patients saddled by methamphetamine use disorder.
Revive is making strides in the development of psilocybin that can be taken in the form of a narrow strip. The company’s research team is also working toward the creation of a psilocybin microneedle patch that makes it that much easier for patients to overcome afflictions with the use of psilocybin.
Psilocybin Will Help Those Recovering From Strokes
Revive is analyzing the use of psilocybin as a treatment modality for patients who have suffered a stroke. The work is being conducted in unison with the University of Wisconsin-Madison. The upcoming Phase I/II clinical study will gauge the feasibility and safety of psilocybin to treat stroke victims. The company will formally propose the study later this winter. The study data will provide insightful information pertaining to the proper dose, efficacy and safety of the drug, paving a path toward future FDA clinical studies that will center on the efficacy of the company’s film strip.
The Role Of Psilocybin In Treating Meth Use Disorder
Revive is studying psilocybin as a treatment modality for patients saddled by meth use disorder. The work takes the shape of a clinical trial agreement performed in unison with the University of Wisconsin-Madison. The study used to evaluate the use of psilocybin to treat meth use disorder will be submitted to the Institutional Review Board for approval.
The Psilocybin Oral Film Strip
Revive’s thin psilocybin strip in development is taken orally. The development of the strip is central to the company’s product development program contained within a feasibility agreement with the industry’s top oral thin film specialist, LTS Lohmann Therapie-Systeme. The hope is that these thin film strips will be used to treat substance abuse, mental illness and neurological disorders. The development of the research prototype is ongoing. The company has set a target date of the fourth quarter in ’22 for the product’s clinical study.
Revive’s brass is hard at work creating a new biosynthetic version of psilocybin using natural biosynthesis enzymatics through a research effort with academicians at North Carolina State University. This platform makes it fast, direct and easy to generate natural products including psilocybin with the use of a specialized enzymatic pathway in E. coli. Revive anticipates completing psilocybin that is of research grade for analysis by the second quarter of ’22, paving a path for clinical studies in ’23.
Revive’s Psilocybin Microneedle Patch
Revive has signed a research agreement with another publicly traded company, PharmaTher Holdings. PharmaTher trades under the symbol of PHRRF. The collaboration agreement will gauge the delivery of psilocybin with microneedle patches for the treatment of neuropsychiatric disorders. The ensuing studies will commence in the fourth quarter of this year.